PATENT CLAIM ANALYSIS

Application Number: 15535222
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2019-01
Patent Classification: ["436", "064000"]

Abstract:
The present disclosure is drawn to methods of diagnosing and classifying pancreatic cancer by examining the expression of particular metabolites that distinguish this disease state from benign disease and periampullary adenocarcinoma.

Claim (Index 1):
A method of distinguishing pancreatic cancer and periampullary adenocarcinoma from benign pancreatic lesions in a subject comprising:\n (a) obtaining a blood, plasma or serum sample; (b) determining the levels of 4 or more of the biomarkers set forth in Table 3 in said sample; and (c) assigning to said sample a classification as\n (i) pancreatic cancer or periampullary adenocarcinoma where one or more markers indicating pancreatic cancer or periampullary adenocarcinoma are elevated; and \n (ii) benign pancreatic lesion where one or more markers indicating benign pancreatic lesions are elevated.

Metadata:
- Claim Count in Document: 10.0
- Percentile: 86.0
- Lexical Diversity: 1.10345
- Patent Class: 436.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14671062', '14753249', '14632480', '13371969', '15116272']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6307168117636943
- 35 USC 102 Novelty (BERT): 0.4671072571933078
- Combined Prediction Score: 0.6143558563066557
- Mean Citation Score: 182.267954
- Max Citation Score: 185.58125
- Similarity Product: 137.17733420841395

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test